EUCTR2008-002113-48-NL进行中（未招募）不适用
A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female = 18 years.
- •2. Clinically definite diagnosis of tuberous sclerosis according to the modified Gomez criteria (Roach et al, 1998; Hyman and Whittemore, 2000) or sporadic LAM (biopsy-proven or compatible chest CT).
- •3. Clinically definite diagnosis of renal angiomyolipoma.
- •4. Presence of at least one angiomyolipoma = 3 cm in its longest diameter using MRI.
- •5. If female and of child bearing potential, documentation of negative pregnancy test prior to enrollment. Sexually active pre-menopausal female patients (and female partners of male patients) must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Angiomyolipoma-related bleeding or embolization during the 6 months prior to randomization.
- •2. History of myocardial infarction, angina or stroke related to atherosclerosis.
- •3. Impaired lung function, defined as any of the following:
- •FEV1 = 70% of predicted, or
- •DLCO = 70% of predicted, or
- •= 88% O2 saturation at rest in room air.
- •4. Chylous ascites sufficient to affect diaphragmatic function or pulmonary function testing.
- •5. Significant hematological or hepatic abnormality (i.e., transaminase levels > 2.5 × the upper limit of normal (ULN), serum bilirubin > 1.5 × ULN, hemoglobin < 9g/dL, platelets < 80,000/mm3, or absolute neutrophil count < 1,000/mm3).
- •6. Pregnancy or breast feeding.
- •7. Use of estrogen containing medications.
- •8. Intercurrent infection at date of randomization.
- •9. Prior history of organ transplant.
- •10. Recent surgery (involving entry into a body cavity or requiring sutures) within the 2 months prior to randomization.
- •11. Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus).
- •12. Use of an investigational drug within the 30 days prior to randomization.
- •13. Uncontrolled hyperlipidemia: Fasting serum cholesterol > 300 mg/dL OR > 7.75 mmol/L AND Fasting triglycerides > 2.5 × ULN.
- •14. Uncontrolled diabetes mellitus as defined by fasting serum glucose > 1.5 × ULN.
- •15. Patients with bleeding diathesis or on oral anti-vitamin K medication (except low dose warfarin).
- •16. Patients with a known history of HIV seropositivity.
- •17. Inability to attend scheduled clinic visits.
- •18. For the purpose of MRI assessments:
- •Ferromagnetic metal implants other than those approved as safe for use in MR scanner (e.g., braces, some types of aneurysm clips, shrapnel).
- •Patients suffering from uncontrollable claustrophobia or physically unable to fit into the machine (e.g., obesity, etc).
- •19. Serum creatinine > 1.5 × ULN.
- •20. History of malignancy in the past two years, other than squamous or basal cell skin cancer.
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer.HR+, HER2- advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2013-003084-61-ATovartis Pharma Services AG650
已完成
3 期
A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM).10027656NL-OMON37228ovartis21
进行中（未招募）
1 期
Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer.HR+, HER2- advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2013-003084-61-SEovartis Pharma Services AG650
尚未招募
不适用
A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.anti social behavior disorderaggressive behavior among chilren and adolescents with externalizing behavior problems.10037173NL-OMON38186niversitair Medisch Centrum Sint Radboud38
进行中（未招募）
1 期
A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)MedDRA version: 9.1Level: LLTClassification code 10051810Term: AngiomyolipomaEUCTR2008-002113-48-FRovartis Pharma Services AG99